136869-07-3

Basic information

• Product Name: N-[4-(hydroxymethyl)benzyl]acetamide
• Synonyms: acetamide, N-[[4-(hydroxymethyl)phenyl]methyl]-
• CAS NO: 136869-07-3
• Molecular Formula: C₁₀H₁₃NO₂
• Molecular Weight: 179.2157
• Mol File: 136869-07-3.mol

Chemical Properties

• Boiling Point: 426.2°C at 760 mmHg
• Flash Point: 211.5°C
• Density: 1.13g/cm³
• Vapor Pressure: 5.05E-08mmHg at 25°C
• Refractive Index: 1.55
• CAS DataBase Reference: N-[4-(hydroxymethyl)benzyl]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-(hydroxymethyl)benzyl]acetamide(136869-07-3)
• EPA Substance Registry System: N-[4-(hydroxymethyl)benzyl]acetamide(136869-07-3)

Safety Data

• Hazardous Substances Data: 136869-07-3(Hazardous Substances Data)

Upstream product

• 39895-56-2 4-hydroxymethyl-benzylamine 
• 108-24-7 acetic anhydride 
• 20686-40-2 4-(acetylamino-methyl)-benzoic acid methyl ester 
• 56-91-7 p-aminomethylbenzoic acid 
• 1205-58-9 4-[(Acetylamino)methyl]-benzoic acid 
• 874-89-5 4-Cyanobenzyl alcohol 
• 100390-63-4 4-(acetamidomethyl)benzyl acetate 
• 18469-52-8 methyl 4-(aminomethyl)benzoate 
• 105-07-7 4-cyanobenzaldehyde 
• 1129-35-7 4-cyanobenzoic acid methyl ester 

Downstream Products

• 223512-41-2 N-(4-chloromethyl-benzyl)-acetamide 
• 223512-42-3 N-(4-((4-phenylpiperazin-1-yl)methyl)phenylmethyl)acetamide 
• 223511-24-8 N-(4-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)phenylmethyl)acetamide 
• 132719-04-1 {4-[(methylamino)methyl]phenyl}methanol 
• 1373162-35-6 C₂₆H₂₂Cl₂N₄O₆S₄ 
• 1192815-20-5 N-(4-(bromomethyl)benzyl)acetamide 

Relevant articles and documents

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

IDO inhibitors

Presently provided are compounds according to the formula (I) or (II), and pharmaceutical compositions comprising the compounds, wherein R1, R4, and R5 are defined herein. Such compounds and compositions are useful for mod

A tetranuclear-zinc-cluster-catalyzed practical and versatile deprotection of acetates and benzoates

A new catalytic deacylation of acetates and benzoates through transesterification with methanol was developed (see scheme). Reactions with various acidand nucleophile-sensitive functional groups proceeded efficiently in the presence of a catalytic amount of the tetranuclear zinc cluster. The present catalysis is applicable to less-reactive tertiary acetates, the deacylation of which is difficult to achieve by transesterification with other catalysts.

Piperazine compounds and medicinal use thereof

The present invention relates to a piperazine compound of the formula wherein R1and R2are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4and R5are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6and R7are each hydrogen, lower alkyl, lower alkyl substituted by halogen, aralkyl, acyl or lower acyl substituted by halogen, R8and R9are each hydrogen or lower alkyl, Y is lower alkylene and the like, and ring A is phenyl, pyrimidyl, thiazolyl, pyridyl, pyrazyl or imidazolyl, a pharmaceutically acceptable salt thereof and pharmaceutical agents containing these compounds. The compound of the present invention has superior TNF-α production inhibitory effect and/or IL-10 production promoting effect, and, since it is free of or shows only strikingly reduced expression of an effect on the central nervous system, the compound is useful as a highly safe and superior TNF-α production inhibitor an/or IL-10 production promoter and is useful as an agent for the prophylaxis or treatment of various diseases caused by abnormal TNF-α production, diseases curable with IL-10, such as chronic inflammatory diseases, acute inflammatory diseases, inflammatory diseases due to infection, autoimmune diseases, allergic diseases, and TNF-α mediated diseases.

Imidazole derivatives

The present invention relates to the imidazole derivative of the following formula (I) wherein R1 is hydrogen, optionally substituted alkyl and the like, R2 is hydrogen, optionally substituted alkyl and the like, R3is optionally substituted heteroaryl, R4 is optionally substituted cycloalkyl, optionally substituted phenyl and the like, provided that when R1 is hydrogen, and R2 and R4 are the same or different and each is phenyl or phenyl substituted by halogen atom, lower alkyl or lower alkoxy, R3 is benzothiazolyl or thiazolyl substituted by phenyl, the imidazole derivative of the following formula (XII) wherein R6 is optionally substituted phenyl or optionally substituted heteroaryl and R7 is substituted phenyl, and pharmaceutically acceptable salts thereof. The compounds of the formulas (I) and (XII) and pharmaceutically acceptable salts thereof of the present invention inhibit IL-4 and IL-5 production by Th2 cells and are effective for the prophylaxis and treatment of allergic diseases such as atopic dermatitis, bronchial asthma, allergic rhinitis and the like.

Novel phenylpiperazine derivatives as dual cytokine regulators with TNF-α suppressing and IL-10 augmenting activity

Phenylpiperazine derivatives were synthesized as dual cytokine regulators with TNF-α suppressing and IL-10 augmenting activity. Lead optimization led to compound 5k having the potent regulatory activity and demonstrating remarkable protective effects against the lethal challenge of LPS in mice, suggesting that 5k would be a promising drug candidate for the treatment of TNF-α associated diseases including septic shock. (C) 2000 Elsevier Science Ltd. All rights reserved.

Chemical Ionization Mass Spectrometry of Bifunctional Compounds. The Behaviour of Bifunctional Compounds on Protonation

Positive-ion chemical ionization mass spectra were measured for simple bifunctional aromatic compounds of the type p-XCH2C6H4CH2Y, where X = NH2, NH(CH3) and N(CH3)2 and Y = OH and OCH3.For each compound, essentially only three peaks of ions, (1+), (1+) and (1+), appeared.The B/E constant linked-scan spectra showed that the stable non-decomposing (1+) had the proton only on the nitrogen-containing functional group.From these data, the relative amounts of total protonation, the ratio of N- and O-protonation and the fraction of fragmenting (1+) can be calculated.The ease of protonation (protonation sus ceptibility) and the reactivity (fragmentation capability) of the respective functional groups are discussed.